Clinical Trials
26 trialsBDH-WM02
Institute of Hematology & Blood Diseases Hospital, China
BDH-MCL01
Institute of Hematology & Blood Diseases Hospital, China
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
University of Miami
ThRiL
Weill Medical College of Cornell University
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Sun Yat-sen University
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
BDHCLL001
Institute of Hematology & Blood Diseases Hospital, China
THRiL for WM
Weill Medical College of Cornell University
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Weill Medical College of Cornell University
BOMB-THROW
Seoul National University Hospital
Thalidomide Maintenance Treatment in DLBCL
Nanfang Hospital, Southern Medical University
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
University of Miami
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
SWOG Cancer Research Network
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Dana-Farber Cancer Institute
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
National Cancer Institute (NCI)
Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
University of Arkansas
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
Medical University of Vienna
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease
Emory University